ClinicalTrials.gg
TerminatedNCT00649220MemAPUpdated Sep 26, 2011Results posted

Memantine and Antipsychotics Use

A Phase 4 interventional study of Memantine in Alzheimer's Disease, sponsored by Merz Pharmaceuticals GmbH. Terminated at 1 site in Germany. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2011-09-26.

Sponsored by Merz Pharmaceuticals GmbH (part of Merz Pharma) · Phase 4, Interventional, and Treatment

Why this study was terminated
Study terminated due to too slow enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing memantine in Alzheimer Disease — 1 open to participants now, 2 under way, none of them phase 3. Memantine · Alzheimer Disease.

Enrollment
31st of 34
19 · median 90
Started
2008
with 4 others
Phase 4
21 of 34
none open now
Registered
14th of 34
by date
Lead sponsor
3 of 34
Merz Pharmaceuticals GmbH

Among the 34 studies testing memantine in Alzheimer Disease, this one is the 31st largest by enrollment, is one of 5 that started in 2008, is one of 21 in phase 4, and was the 14th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 34 studies testing memantine in Alzheimer Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About memantine

Memantine: first FDA approval 2003 (NAMENDA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing memantine in Alzheimer Disease, or all of them as a file.
02

Study summary

To investigate the potential to reduce concomitant antipsychotic medication use in subjects with moderate dementia of Alzheimer's type, treated with memantine.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Current diagnosis of probable Alzheimer's disease consistent with NINCDS-ADRDA criteria or with DSM IV TR criteria for Dementia of the Alzheimer's type.
  • MRI or CT scan supporting the diagnosis of DAT without indications of any relevant other CNS disorders.
  • Patients treated with any acetylcholinesterase inhibitor (AChEI) man be included.
  • The patient should have German as a mother-tongue or at least speak the language fluently.

Exclusion criteria

Exclusion criteria:

  • Evidence (including CT/MRI results) of any central nervous system disease other than Alzheimer's disease.
  • Modified Hachinski Ischemia score greater than 4 at screening.
  • Intake of any medication that is in combination with memantine.
  • Treatment with depot antipsychotics.
  • History of severe drug allergy, or , or patients with known hypersensitivity to memantine, amantadine or lactose.
  • Known or suspected history of alcoholism or drug abuse within the past 10 years.
  • Previous treatment with memantine or participation in an study with memantine.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Memantine

    Drug: Memantine

Interventions

  • memantine tablets, twice a day (bid), for 20 weeks

06

What researchers measure

Primary outcomes

  1. Maximum Dose Reduction of Antipsychotics (AP) in Percent of Defined Daily Dose (DDD) From Baseline to a Post-baseline Visit at Which the Value of the Visual Analogue Scale (VAS) Compared With the Baseline Value Was =< 15 Percent.

    VAS: see #8. Mean "percent of the total Defined Daily Dose (DDD)", averaged over one week, was calculated. Total DDD was calculated as sum of DDD for each AP drug. DDD is the assumed average maintenance dose per day defined by WHO. The reduction of AP Δ \[percent\] was calculated as a difference between the mean total DDD recorded at baseline and the mean total DDD recorded at the respective week. Measurements from those post-baseline visits were taken into account only when the value of the VAS was not substantially worse compared to baseline.

    Time frame: Week 8-20 post baseline

Secondary outcomes

  1. Reduction of Antipsychotic Drug Dose From Baseline to Week 8, 12, 16 and/or 20.

    See #1 and #8. Change of \<0 reveals a reduction of AP compared to baseline.

    Time frame: Week 8-20 post Baseline

  2. Change in the Mini-Mental State Examination (MMSE) Score Value From Baseline to Week 20.

    MMSE is a brief, physician-administered scale, designed for measuring the cognitive functions, such as: orientation, memory, attention, naming, and comprehension. The scoring range of MMSE is 0 to 30 points. A score of 23 or lower is indicative of cognitive impairment. Change of \>0 reveals an improvement compared to baseline.

    Time frame: Week 20 post baseline

  3. Change of "Test for the Early Detection of Dementia With Discrimination From Depression [TE4D]" Score Value From Baseline to Week 4, 8, 12, 16, and/or 20 - First Part: Total Dementia

    TE4D is a psychometric, physician-administered test that is used for both screening subjects with early dementia and monitoring the clinical progress of the disease. The first part consists of 9 items, which assess different symptoms associated with dementia such as memory, time-orientation, etc. The scoring range is 0 to 50 points. A score of 35 or lower is an indication of dementia. A change \>0 represents an improvement.

    Time frame: Week 4-20 post baseline

  4. Change of "Test for the Early Detection of Dementia With Discrimination From Depression [TE4D]" Score Value From Baseline to Week 4, 8, 12, 16, and/or 20 - Second Part: Total Depression

    TE4D is a psychometric, physician-administered test that is used for both screening subjects with early dementia and monitoring the clinical progress of the disease. The second part consists of a proxy rating and a self-assessment rating. The scoring range of each rating is 1 to 10. The maximum total score of 10 corresponds to severe depression. A change \<0 reveals an improvement compared to baseline.

    Time frame: Week 4-20 post Baseline

  5. Change of Modified Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADLB19) Score Value From Baseline to Week 4, 8, 12, 16, and/or 20.

    The modified ADCS-ADL19 is comprehensive battery of ADL questions aimed to measure the functional ability of subjects with Dementia of Alzheimer's type over a broad range of dementia severity. It has a scoring range of 0 to 54 with the lower scores indicating greater functional impairment. Each ADL item was rated from the highest level of independent performance to complete loss. Change of \>0 reveals an improvement compared to baseline.

    Time frame: Week 4-20 post Baseline

  6. Change of Nurses' Observation Scale for Geriatric Patients [NOSGER] Total Score Value From Baseline to Week 4, 8, 12, 16, and/or 20

    NOSGER is a comprehensive scale, which contains 30 items of behavior, each rated on a 5-point scale according to the frequency of occurrence by direct observation. Item scores are summarized into 6 dimension scores: memory, instrumental activities of daily life, self-care, mood, social behavior, and disturbing behavior. The NOSGER has a scoring range of 30 to 150 with the higher scores indicating worse subject's status. The items in each group are rated for their frequency ranging from 1 (never) to 5 (always). A change of \<0 reveals an improvement compared to baseline.

    Time frame: Week 4-20 post Baseline

  7. Change in the VAS Score From Baseline to Week 8, 12, 16 and/or 20.

    VAS is a report device to measure the subject's burden caused by behavioral symptoms. To measure the burden on the VAS only the first 3 items of the Neuropsychiatric Inventory (NPI) Questionnaire were considered (delusions, hallucinations (visual and auditory), and agitation / aggression). The VAS consists of a 100 mm horizontal line, anchored at the ends with the reference "not at all" and "extremely". The VAS score was determined by measuring in mm from the left hand end of the line to the point, where the investigator had marked the magnitude of a subject's burden.

    Time frame: Week 8-20 post Baseline

07

Results

Posted Sep 13, 2011
Limitations and caveats
Early termination due to too slow enrollment lead to a small sample size, limiting the ability for confirmatory analysis. All analysis of the primary efficacy endpoint were treated as exploratory.

Participant flow

Participant flow — Overall Study
MilestoneMemantine
Started19
Completed16
Not completed3
Withdrew: Adverse event2
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryMaximum Dose Reduction of Antipsychotics (AP) in Percent of Defined Daily Dose (DDD) From Baseline to a Post-baseline Visit at Which the Value of the Visual Analogue Scale (VAS) Compared With the Baseline Value Was =< 15 Percent.

VAS: see #8. Mean "percent of the total Defined Daily Dose (DDD)", averaged over one week, was calculated. Total DDD was calculated as sum of DDD for each AP drug. DDD is the assumed average maintenance dose per day defined by WHO. The reduction of AP Δ \[percent\] was calculated as a difference between the mean total DDD recorded at baseline and the mean total DDD recorded at the respective week. Measurements from those post-baseline visits were taken into account only when the value of the VAS was not substantially worse compared to baseline.

Time frame:
Week 8-20 post baseline
Reported as:
Mean · Percent of daily dose [DDD]
Maximum Dose Reduction of Antipsychotics (AP) in Percent of Defined Daily Dose (DDD) From Baseline to a Post-baseline Visit at Which the Value of the Visual Analogue Scale (VAS) Compared With the Baseline Value Was =< 15 Percent.
Percent of daily dose [DDD]Memantine
Maximum Dose Reduction of Antipsychotics (AP) in Percent of Defined Daily Dose (DDD) From Baseline to a Post-baseline Visit at Which the Value of the Visual Analogue Scale (VAS) Compared With the Baseline Value Was =< 15 Percent.-13.9 ± 13.58
Statistical analysis
  • Memantine · t-test, 2 sided · p = 0.22626
  • Memantine · Wilcoxon signed rank test · p = 0.34192
SecondaryReduction of Antipsychotic Drug Dose From Baseline to Week 8, 12, 16 and/or 20.

See #1 and #8. Change of \<0 reveals a reduction of AP compared to baseline.

Time frame:
Week 8-20 post Baseline
Reported as:
Mean · Percent of daily dose [DDD]
Reduction of Antipsychotic Drug Dose From Baseline to Week 8, 12, 16 and/or 20.
Percent of daily dose [DDD]Memantine
Week 8-4.4 ± 5.53
Week 12-8.2 ± 12.38
Week 16-10.6 ± 13.49
Week 20-14.9 ± 15.05
SecondaryChange in the Mini-Mental State Examination (MMSE) Score Value From Baseline to Week 20.

MMSE is a brief, physician-administered scale, designed for measuring the cognitive functions, such as: orientation, memory, attention, naming, and comprehension. The scoring range of MMSE is 0 to 30 points. A score of 23 or lower is indicative of cognitive impairment. Change of \>0 reveals an improvement compared to baseline.

Time frame:
Week 20 post baseline
Reported as:
Mean · units on a scale
Change in the Mini-Mental State Examination (MMSE) Score Value From Baseline to Week 20.
units on a scaleMemantine
Change in the Mini-Mental State Examination (MMSE) Score Value From Baseline to Week 20.0.9 ± 3.44
SecondaryChange of "Test for the Early Detection of Dementia With Discrimination From Depression [TE4D]" Score Value From Baseline to Week 4, 8, 12, 16, and/or 20 - First Part: Total Dementia

TE4D is a psychometric, physician-administered test that is used for both screening subjects with early dementia and monitoring the clinical progress of the disease. The first part consists of 9 items, which assess different symptoms associated with dementia such as memory, time-orientation, etc. The scoring range is 0 to 50 points. A score of 35 or lower is an indication of dementia. A change \>0 represents an improvement.

Time frame:
Week 4-20 post baseline
Reported as:
Mean · units on a scale
Change of "Test for the Early Detection of Dementia With Discrimination From Depression [TE4D]" Score Value From Baseline to Week 4, 8, 12, 16, and/or 20 - First Part: Total Dementia
units on a scaleMemantine
Week 4-2.3 ± 7.64
Week 8-0.3 ± 5.31
Week 12-1.3 ± 4.48
Week 160.7 ± 5.39
Week 201.4 ± 4.2
SecondaryChange of "Test for the Early Detection of Dementia With Discrimination From Depression [TE4D]" Score Value From Baseline to Week 4, 8, 12, 16, and/or 20 - Second Part: Total Depression

TE4D is a psychometric, physician-administered test that is used for both screening subjects with early dementia and monitoring the clinical progress of the disease. The second part consists of a proxy rating and a self-assessment rating. The scoring range of each rating is 1 to 10. The maximum total score of 10 corresponds to severe depression. A change \<0 reveals an improvement compared to baseline.

Time frame:
Week 4-20 post Baseline
Reported as:
Mean · units on a scale
Change of "Test for the Early Detection of Dementia With Discrimination From Depression [TE4D]" Score Value From Baseline to Week 4, 8, 12, 16, and/or 20 - Second Part: Total Depression
units on a scaleMemantine
Week 42.5 ± 4.84
Week 81.6 ± 3.97
Week 12-0.1 ± 3.26
Week 16-0.2 ± 2.07
Week 20-0.4 ± 2.09
SecondaryChange of Modified Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADLB19) Score Value From Baseline to Week 4, 8, 12, 16, and/or 20.

The modified ADCS-ADL19 is comprehensive battery of ADL questions aimed to measure the functional ability of subjects with Dementia of Alzheimer's type over a broad range of dementia severity. It has a scoring range of 0 to 54 with the lower scores indicating greater functional impairment. Each ADL item was rated from the highest level of independent performance to complete loss. Change of \>0 reveals an improvement compared to baseline.

Time frame:
Week 4-20 post Baseline
Reported as:
Mean · Units on a Scale
Change of Modified Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADLB19) Score Value From Baseline to Week 4, 8, 12, 16, and/or 20.
Units on a ScaleMemantine
Week 4-0.7 ± 6.33
Week 82.2 ± 8.09
Week 123.8 ± 11.07
Week 163.8 ± 11.27
Week 202.4 ± 11.08
SecondaryChange of Nurses' Observation Scale for Geriatric Patients [NOSGER] Total Score Value From Baseline to Week 4, 8, 12, 16, and/or 20

NOSGER is a comprehensive scale, which contains 30 items of behavior, each rated on a 5-point scale according to the frequency of occurrence by direct observation. Item scores are summarized into 6 dimension scores: memory, instrumental activities of daily life, self-care, mood, social behavior, and disturbing behavior. The NOSGER has a scoring range of 30 to 150 with the higher scores indicating worse subject's status. The items in each group are rated for their frequency ranging from 1 (never) to 5 (always). A change of \<0 reveals an improvement compared to baseline.

Time frame:
Week 4-20 post Baseline
Reported as:
Mean · Units on a scale
Change of Nurses' Observation Scale for Geriatric Patients [NOSGER] Total Score Value From Baseline to Week 4, 8, 12, 16, and/or 20
Units on a scaleMemantine
Week 4-0.4 ± 10.9
Week 8-2.1 ± 10.31
Week 12-5.4 ± 13.29
Week 16-8.4 ± 18.74
Week 20-7.9 ± 19.02
SecondaryChange in the VAS Score From Baseline to Week 8, 12, 16 and/or 20.

VAS is a report device to measure the subject's burden caused by behavioral symptoms. To measure the burden on the VAS only the first 3 items of the Neuropsychiatric Inventory (NPI) Questionnaire were considered (delusions, hallucinations (visual and auditory), and agitation / aggression). The VAS consists of a 100 mm horizontal line, anchored at the ends with the reference "not at all" and "extremely". The VAS score was determined by measuring in mm from the left hand end of the line to the point, where the investigator had marked the magnitude of a subject's burden.

Time frame:
Week 8-20 post Baseline
Reported as:
Mean · Units on a scale [cm]
Change in the VAS Score From Baseline to Week 8, 12, 16 and/or 20.
Units on a scale [cm]Memantine
Week 8-1.5 ± 1.94
Week 12-1.7 ± 2.53
Week 16-1.2 ± 2.86
Week 20-1.4 ± 2.46

Adverse events

Collected over All SAEs/AEs from baseline until 4 weeks after end of treatment (in total 20 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Memantine—2/19 (10.5%)7/19 (36.8%)
Most frequent serious events
Most frequent serious events
EventMemantine
DepressionPsychiatric disorders1/19
AgitationPsychiatric disorders1/19
Sleep DisturbancesPsychiatric disorders1/19
Most frequent other events
Showing 10 of 13
Most frequent other events
EventMemantine
FatigueGeneral disorders2/19
AgitationPsychiatric disorders1/19
AnxietyPsychiatric disorders1/19
InsomniaPsychiatric disorders1/19
ListlessPsychiatric disorders1/19
Sleep-related eating disorderPsychiatric disorders1/19
DiarrhoeaGastrointestinal disorders1/19
Epigastric discomfortGastrointestinal disorders1/19
Haemorrhoidal haemorrhageGastrointestinal disorders1/19
NauseaGastrointestinal disorders1/19

Baseline characteristics

Age Continuous
Age Continuous(years)Memantine
Mean72.4 ± 9.7
Age, Customized
Age, Customized(participants)Memantine
Between 50 and 85 years19
Sex: Female, Male
Sex: Female, Male(Participants)Memantine
Female10
Male9
Region of Enrollment
Region of Enrollment(participants)Memantine
Germany19
08

Study locations

1 site
  • Alexianer Hospital
    Krefeld, North-Rhine-Westphalia, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of May 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2011, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2008
First posted
Apr 1, 2008
Start
Jul 2008
Primary completionActual
May 2009
CompletionActual
Jun 2009
Results first posted
Sep 13, 2011
Last update
Sep 26, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00649220
Responsible party
Sponsor
First posted
Apr 1, 2008
Start date
Jul 2008
Primary completion
May 2009
Completion
Jun 2009
Results posted
Sep 13, 2011
Last update
Sep 26, 2011

Study contacts

Medical Expert
study director · Merz Pharmaceuticals GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Memantine

Start the discussion